Dr. Krueger is Director of the Tuberous Sclerosis Clinic, Associate Professor of Clinical Pediatrics and Neurology, and Associate Director of Research in Neurology at Cincinnati Children's Hospital Medical Center. He also was a founding member of the Tuberous Sclerosis Complex Clinical Research Consortium and served as its first director from 2011 to 2013 and continues as a member of its Senior Advisory Board. Dr. Krueger received PhD and MD degrees from Saint Louis University in 2000 and 2002, respectively, and completed combined residency in pediatrics, neurology, and child neurology at Cincinnati Children's Hospital Medical Center (CCHMC) and the University of Cincinnati College of Medicine in 2007. Active preclinical, translational, and clinical research projects with both CCHMC and external collaborators are aimed at better understanding the underlying molecular mechanisms involved in TSC disease pathogenesis and treatment outcomes. The ultimate objective is to develop treatment strategies that reverse or prevent disease progression and secondary complications. Dr. Krueger was a leading investigator for the landmark clinical trial using mTOR inhibitors to treat subependymal giant cell astrocytoma's that led to the first ever FDA-approved treatment for TSC in 2010. Currently, Dr. Krueger is principal investigator, project leader, or major co-investigator for multiple TSC-focused clinical studies funded by the National Institutes of Health, including the TSC Autism Center of Excellence Network (TACERN).